Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
NanoViricides, Inc. (NYSE American: NNVC) Just Landed On The Street Ideas Watchlist This Morning
—Tuesday, September 29, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Take A Look At (NNVC) While It’s Still Early…
September 29, 2026 Dear Reader, With a fresh Phase II development now putting this small clinical-stage name in focus, NanoViricides, Inc. (NYSE American: NNVC) is one we’ll be watching closely from the opening bell. The timing is especially notable as NV-387 moves into active patient dosing during a major Eb-ola outbreak in Central Africa. The world just watched the largest Eb-ola outbreak in history tear across Central Africa… And right now, this small clinical-stage company may have the only oral anti-vi-ral in active human trials to fight it. NanoViricides, Inc. (NYSE American: NNVC) announced on September 28th that its Phase II clinical trial of NV-387 Oral Gummies for the treatment of Eb-ola has begun enrolling and dosing patients at an Eb-ola Treatment Center in the Ituri province of the Democratic Republic of Congo. That's not a planned submission. That's not a regulatory filing. That's patients receiving an oral anti-vi-ral dr-ug in the middle of the worst Eb-ola crisis the world has ever recorded… NanoViricides, Inc. (NYSE American: NNVC) is topping our watchlist this morning—Tuesday, September 29, 2026. 
According to Yahoo Finance, (NYSE American: NNVC) has a float less than 22M listed as available to the public—with a float that small, the potential exists for big moves if demand begins to shift. Noble Capital Markets initiated coverage of (NNVC) with an "Outperform" rating and a $6 target on July 6, 2026, suggesting substantial upside from current levels. An Outbreak That Rewrote the Record Books
The numbers here are staggering… As of September 23, 2026, the WHO has confirmed 7,890 cases and 3,799 deaths from the Bundibugyo Eb-olavi-rus in DRC. The crude fatality rate sits at roughly 48%. The actual probability of an infected person dying is closer to 67%, with about one-third of patients recovering. This is now the fastest-growing Eb-ola outbreak ever documented, and it has spread across at least six provinces in DRC while threatening South Sudan. The WHO declared this a Public Health Emergency of International Concern back on May 17, 2026. And here's what makes the situation even more complicated… There is no approved treatment or vaccine for this particular variant of the Bundibugyo Eb-olavi-rus. The only other clinical trial underway, called "PARTNERS," requires intravenous infusions of antibody cocktails and remdesivir, which are inherently difficult to scale in resource-poor settings. NV-387 is currently the only orally administered anti-vi-ral in clinical trials for Eb-ola, according to the company. That distinction matters enormously when you're trying to reach patients in remote provinces with limited medical infrastructure. Targeting the Entry Point
What separates NV-387 from conventional anti-vi-rals is the mechanism… Most anti-vi-ral approaches target specific parts of the vi-rus itself, which means the vi-rus can escape through mutation. NV-387 takes a different path entirely. It mimics the host-side feature called heparan sulfate proteoglycan (HSPG) that over 90-95% of human pathogenic vi-ruses require for infecting cells. The company describes it as a dr-ug that "looks like a cell" to the vi-rus, trapping and neutralizing it before infection can take hold. Because NV-387 mimics the host rather than targeting the vi-rus directly, the vi-rus is highly unlikely to develop resistance, no matter how much it mutates in the field. And this isn't just theoretical… In preclinical studies, orally administered NV-387 was found to be superior to intravenously delivered remdesivir in extending survival in lethally infected animals in a separate vi-ral disease model. The NV-387 Oral Gummies formulation dissolves naturally in the mouth without requiring water or swallowing effort, which simplifies delivery for patients who are severely ill. A Pipeline Taking Shape
The Eb-ola trial grabbed headlines, but the pipeline at NanoViricides, Inc. (NYSE American: NNVC) runs much deeper than a single indication… Just five days before the Eb-ola dosing announcement, the company reported that its Phase II clinical trial of NV-387 for Mpox had also begun enrolling patients in DRC. That makes two separate Phase II clinical trials running simultaneously in the same country, using the same broad-spectrum dr-ug candidate. The Mpox trial is being led by Prof. Vivi Maketa Tevuzula, a Bayer Foundation Early Excellence in Science Award recipient, based at the University of Kinshasa. And the pipeline doesn't stop there… The company disclosed in August that the FDA has granted NV-387 a "Rare Pediatric Disease Dr-ug" Designation for the treatment of Measles, which could entitle the company to a Priority Review Voucher upon a successful New Dr-ug Application. To put that in perspective, a recent Priority Review Voucher sold for $195M. NV-387 has also received Orphan Dr-ug Designation from the FDA for Measles and has applied for Orphan Dr-ug Designation for Mpox. 
The global anti-vi-ral market was valued at roughly $65B in 2026 and is projected to reach approximately $90B by 2035, according to Global Market Insights. A broad-spectrum anti-vi-ral platform that could potentially address multiple major vi-ral diseases from a single compound represents a meaningful angle within that expanding space. "NV-387, our broad-spectrum anti-vi-ral, is designed to mimic human cells to trap and destroy the vi-rus," said Anil R. Diwan, PhD, President and Executive Chairman, adding, "This single dr-ug can target over 90-95% of human pathogenic vi-ruses." 7 Reasons Why We're Watching (NNVC) This Morning —Tuesday, September 29, 2026…
1. Small-Float: According to Yahoo Finance, less than 22M shares exist in the public float, the potential exists for big moves if demand begins to shift. 2. Phase II Eb-ola Trial Now Dosing Patients: NV-387 Oral Gummies began enrollment and dosing on or about September 23, 2026, at an Eb-ola Treatment Center in DRC's Ituri province, making it the only oral anti-vi-ral in active Eb-ola trials. 3. Phase II Mpox Trial Also Underway: A second Phase II trial of NV-387 for Mpox has begun enrolling patients in DRC, led by a Bayer Foundation award-winning principal investigator. 4. FDA Rare Pediatric Disease Dr-ug Designation for Measles: The RPDD could enable a Priority Review Voucher upon approval, with recent vouchers selling for $195M. 5. Broad-Spectrum Mechanism That Vi-ruses Cannot Escape: NV-387 mimics host-cell HSPG receptors, targeting the same entry point used by over 90-95% of human pathogenic vi-ruses, making resistance highly unlikely. 6. Oral Delivery Advantage Over Infusion-Based Competitors: NV-387 Oral Gummies dissolve in the mouth and require no water, IV lines, or trained infusion staff, a decisive advantage in resource-limited outbreak settings. 7. Analyst Target Suggests Significant Upside Potential: Noble Capital Markets initiated coverage of (NNVC) with an "Outperform" rating and a $6 target on July 6, 2026, suggesting substantial upside from current levels. Take A Look At (NNVC) While It’s Still Early… 
The setup around NanoViricides, Inc. (NYSE American: NNVC) is becoming increasingly difficult to ignore. A public float of less than 22M shares already puts (NNVC) in a category where shifts in demand can matter quickly. Now add two separate Phase II programs moving forward in DRC at the same time... NV-387 Oral Gummies are already being administered in the company's Eb-ola study, while a second Phase II program for Mpox has also begun enrolling patients. The same candidate has received FDA Rare Pediatric Disease Dr-ug Designation for Measles, potentially opening the door to a Priority Review Voucher if the applicable approval requirements are ultimately met. Then there is the underlying platform itself. NV-387 is designed to mimic host-cell features used during vi-ral attachment, giving the company a broad-spectrum approach that management believes could apply across a wide range of pathogenic vi-ruses. Its oral gummy formulation adds another layer, particularly in areas where water, IV infrastructure, and trained infusion personnel may be limited. And alongside all of that, Noble Capital Markets initiated coverage of (NNVC) with an Outperform rating and a $6 target. Taken together, these are several separate developments converging around one small clinical-stage company at the same time. We have all eyes on (NNVC) this morning. Take a look at (NNVC) while it’s still early. Sincerely, Paul Prescott
Co-Founder & Managing Editor
Street Ideas Newsletter |
0 التعليقات:
إرسال تعليق